The fibrotic tumor stroma
Mitsuo Yamauchi,1 Thomas H. Barker,2 Don L. Gibbons,3,4 and Jonathan M. Kurie3
1Oral and Craniofacial Health Sciences, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
2Department of Biomedical Engineering, School of Engineering and Applied Sciences and School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
3Department of Thoracic/Head and Neck Medical Oncology and
4Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Jonathan M. Kurie, MD Anderson Cancer Center, Box 432, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 713.745.6747; E-mail: jkurie@mdanderson.org.
Find articles by Yamauchi, M. in: JCI | PubMed | Google Scholar
1Oral and Craniofacial Health Sciences, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
2Department of Biomedical Engineering, School of Engineering and Applied Sciences and School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
3Department of Thoracic/Head and Neck Medical Oncology and
4Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Jonathan M. Kurie, MD Anderson Cancer Center, Box 432, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 713.745.6747; E-mail: jkurie@mdanderson.org.
Find articles by Barker, T. in: JCI | PubMed | Google Scholar
1Oral and Craniofacial Health Sciences, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
2Department of Biomedical Engineering, School of Engineering and Applied Sciences and School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
3Department of Thoracic/Head and Neck Medical Oncology and
4Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Jonathan M. Kurie, MD Anderson Cancer Center, Box 432, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 713.745.6747; E-mail: jkurie@mdanderson.org.
Find articles by Gibbons, D. in: JCI | PubMed | Google Scholar
1Oral and Craniofacial Health Sciences, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
2Department of Biomedical Engineering, School of Engineering and Applied Sciences and School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
3Department of Thoracic/Head and Neck Medical Oncology and
4Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Jonathan M. Kurie, MD Anderson Cancer Center, Box 432, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Phone: 713.745.6747; E-mail: jkurie@mdanderson.org.
Find articles by Kurie, J. in: JCI | PubMed | Google Scholar
First published January 2, 2018 - More info
J Clin Invest. 2018;128(1):16–25. https://doi.org/10.1172/JCI93554.
Copyright © 2018, American Society for Clinical Investigation
Intratumoral fibrosis results from the deposition of a cross-linked collagen matrix by cancer-associated fibroblasts (CAFs). This type of fibrosis has been shown to exert mechanical forces and create a biochemical milieu that, together, shape intratumoral immunity and influence tumor cell metastatic behavior. In this Review, we present recent evidence that CAFs and tumor cells are regulated by provisional matrix molecules, that metastasis results from a change in the type of stromal collagen cross-link, and that fibrosis and inflammation perpetuate each other through proteolytic and chemotactic mediators released into the tumor stroma. We also discuss aspects of the emerging biology that have potential therapeutic value.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)